
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is well-positioned in the health insurance sector due to its focus on improving access, cost, and quality of care, along with its commitment to diversity and sustainability. The company's strong financial performance, with a beat on 1Q26 EPS and a raised full-year guidance, points to its ability to manage medical costs and grow its membership. Additionally, Cigna's Evernorth's specialty platform, growing 8-12% annually, is a key element of the company's story and could be a potential catalyst for future growth.
Bears say
Cigna Group is facing potential headwinds in its PBM and specialty pharmacy services despite strong sales and retention in the 2027 selling season due to a potential loss in government contracts and increased investments in its rebate-free PBM model. The company's valuations and earnings estimates are also a cause for concern, with its long-term EPS growth projected in the lower half of its range and a target PE multiple lower than that of peers with significant government business. The implementation of AI and success in identifying complex patients may provide some cost savings, but it is too early to determine their long-term impact on the company's financial performance. Investors should closely monitor developments in Cigna's PBM contracts and the effectiveness of its new PBM model in order to fully evaluate its growth and sustainability prospects.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares